Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2017-001355-31Phase 2Terminated
Phase 2, randomised trial of oxygen in ischemic stroke (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Ischemic core growth from baseline to 24 hours. Started Jul 2018; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2017-001355-31.